Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Adam Schapmann

Physician Assistant Kearney, NE Physician Assistant

NPI 1376881615 CMS profile 10995738

2810 W 35Th St, Ste 1, Kearney, NE 68845

Open in the dashboard

General payments

$4,849

65 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Schapmann of Kearney, NE is reported in the CMS Open Payments database as having received $4,849 across 65 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,478 36
2024 General $1,320 15
2023 General $41 2
2022 General $2,011 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Schapmann
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Adam Schapmann were reported at $1,478. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Adam Schapmann Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $2,011 $155 $48–$522 $149
2023 $41 $167 $52–$557 $160
2024 $1,320 $178 $55–$600 $164
2025 $1,478 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $2,113 23 payments
  2. Stryker Corporation $2,045 13 payments
  3. Boston Scientific Corporation $173 8 payments
  4. Abiomed $112 3 payments
  5. Abbott Laboratories $73 4 payments
  6. Edwards Lifesciences Corporation $56 2 payments
  7. Inari Medical, Inc. $51 2 payments
  8. Baxter Healthcare $33 1 payment
  9. Biotronik Inc. $33 2 payments
  10. Cardiva Medical, Inc. $28 1 payment
  11. Other $132 6 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Travel and Lodging $2,835 14 payments
  2. Food and Beverage $1,817 49 payments
  3. Education $198 2 payments
Products named General payments · program years 2022–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $1,951 11 payments
  2. ASNIS $709 1 payment
  3. AEQUALIS PERFORM $709 1 payment
  4. SYMPLICITY G3 $315 7 payments
  5. FLOWTRIEVER CATHETER, S $85 3 payments
  6. CT THROMBECTOMY SYSTEM KIT $85 3 payments
  7. WATCHMAN FLX $77 4 payments
  8. Impella $68 1 payment
  9. ORTHOLOC 3DI $60 1 payment
  10. PROPHECY $60 1 payment
  11. Other $582 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

264

Median for Physician Assistant: 241

Drug cost

$4,653

Median for Physician Assistant: $4,110

Branded share of claims

17.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 14 $3,789
Tramadol Hcl Generic 67 $253
Methocarbamol Generic 31 $147
Ondansetron Odt Ondansetron Brand 22 $124
Hydromorphone Hcl Generic 39 $121
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $78
Meloxicam Generic 24 $51
Ondansetron Hcl Generic 12 $37
Amoxicillin Generic 32 $34
Cephalexin Generic 12 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$4,220

Of which drugs: $691

Medicare patients

60

Average age 75

Services billed

176

29 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 30%
Depression 25%
Diabetes 22%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 80 mg J1040 Office 12 15 $84

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record